Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Metadata
Title
Retrotransposon-derived elements in the mammalian genome: A potential source of disease
Authors
R. Druker
E. Whitelaw
Publication date
01-05-2004
Publisher
Kluwer Academic Publishers
Published in
Journal of Inherited Metabolic Disease / Issue 3/2004
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1023/B:BOLI.0000031096.81518.66

Other articles of this Issue 3/2004

Journal of Inherited Metabolic Disease 3/2004 Go to the issue

Legacy

Congenital disorders of glycosylation (CDG): Update and new developments

OriginalPaper

After the genome—the phenome?

OriginalPaper

The genetics and pathophysiology of diabetes mellitus type II

OriginalPaper

Enzyme replacement and enhancement therapies for lysosomal diseases

OriginalPaper

Protein substitutes for PKU: What's new?

OriginalPaper

Treatment of lysosomal storage disorders: Cell therapy and gene therapy

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits